Zevra Therapeutics
ZVRA
11.08
+0.35
+3.26%
Zevra Therapeutics
US · ZVRA
#3562 by market cap
11.08
+0.35
+3.26%
Live - 5344 symbols - heartbeat 329s ago
· 2026-10-08 09:19
Pre-market
11.07
-0.09%
After-hours
11.19
+0.99%
- Market cap
- 657.97M
- P/E (TTM)i
- 11.91
- P/Bi
- 3.02
- EPSi
- 1.35
- Div yieldi
- 0.00%
- 52W posi
- 44%
Reader sentiment
Are you bullish or bearish on ZVRA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 3.4 percentage points.
Institutional ownership
- Held by institutions
- 77.23% -3.41pp
- Institutions
- 192 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund52.84%
Hedge Fund19.27%
Public Company3.10%
Private Company1.46%
Individual/Insider1.17%
Insurance Company0.24%
Government Pension Fund0.21%
Family Office/Trust0.11%
Other21.60%
Top holders as of 2026-06-30
BlackRock
8.60% · 5.11M sh
FMR
8.28% · 4.92M sh
Woodline Partners LP
8.06% · 4.79M sh
Vanguard Capital Management, LLC
5.12% · 3.04M sh
Nantahala Capital Management, LLC
3.03% · 1.80M sh
State Street Global Advisors
2.83% · 1.68M sh
Geode Capital Management, LLC
2.59% · 1.54M sh
D. E. Shaw & Co., L.P.
2.20% · 1.31M sh
Qube Research & Technologies Ltd
2.09% · 1.24M sh
Legal & General Investment Management
2.02% · 1.20M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 33 buys · 17 sells
| Name | Role | Stake |
|---|---|---|
| Neil McFarlane | Chief Executive Officer | 0.65% |
| John Bode | Independent Director | 0.21% |
| Joshua Schafer | Chief Commercial Officer & Executive VP of Business Development | 0.10% |
| Rahsaan Thompson | Chief Legal Officer, Secretary & Compliance Officer | 0.06% |
| Timothy Sangiovanni | Officer | 0.05% |
| Thomas Anderson | Director | 0.03% |
| Alvin Shih | Director | 0.03% |
| Adrian Quartel | Chief Medical Officer | 0.02% |
| Tamara Favorito | Independent Chairperson | 0.01% |
| Corey Watton | Independent Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-13 | Rahsaan Thompson | Chief Legal Officer, Secretary & Compliance Officer | Automatic Disposition | -42,666 | $11.13 |
| 2026-08-09 | Corey Watton | Independent Director | Derivative Exercise and Sale | -12,300 | $4.97–11.25 |
| 2026-06-21 | Rahsaan Thompson | Chief Legal Officer, Secretary & Compliance Officer | Derivative Exercise and Sale | -34,557 | $12.68 |
| 2026-06-20 | Rahsaan Thompson | Chief Legal Officer, Secretary & Compliance Officer | Derivative Exercise and Retained | +32,110 | -- |
| 2026-06-03 | Douglas Calder | Independent Director | Other Derivative Acquisition | +30,000 | $11.17 |
| 2026-06-03 | Tamara Favorito | Independent Chairperson | Other Derivative Acquisition | +30,000 | $11.17 |
| 2026-06-03 | Corey Watton | Independent Director | Other Derivative Acquisition | +30,000 | $11.17 |
| 2026-06-03 | Alicia Secor | Director | Other Derivative Acquisition | +30,000 | $11.17 |
| 2026-06-03 | Thomas Anderson | Director | Other Derivative Acquisition | +30,000 | $11.17 |
| 2026-06-03 | Alvin Shih | Director | Other Derivative Acquisition | +30,000 | $11.17 |
| 2026-05-27 | Timothy Sangiovanni | Officer | Other Derivative Acquisition | +20,000 | -- |
| 2026-05-27 | Timothy Sangiovanni | Officer | Other Derivative Acquisition | +40,000 | $11.40 |
| 2026-05-10 | Rahsaan Thompson | Chief Legal Officer, Secretary & Compliance Officer | Automatic Disposition | -1,794 | $11.30 |
| 2026-03-23 | John Bode | Independent Director | Derivative Exercise and Retained | +78,400 | $4.89–4.97 |
| 2026-03-17 | Justin Renz | Chief Financial Officer | Other Derivative Acquisition | +300,000 | $9.55 |
| 2026-02-08 | Neil McFarlane | Chief Executive Officer | Derivative Exercise and Sale | -14,625 | $8.56 |
| 2026-02-06 | Neil McFarlane | Chief Executive Officer | Derivative Exercise and Retained | +22,875 | -- |
| 2026-02-02 | Timothy Sangiovanni | Officer | Automatic Disposition | -3,000 | $9.18 |
| 2026-02-02 | Joshua Schafer | Chief Commercial Officer & Executive VP of Business Development | Automatic Disposition | -10,500 | $9.19 |
| 2026-02-01 | Neil McFarlane | Chief Executive Officer | Derivative Exercise and Sale | -91,000 | $9.38 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:19:14 · For reference only, not investment advice and not tailored to your situation.